Short-term safety of tranexamic acid use in posterior cervical decompression and fusion surgery. (August 2019)

• Record Type: Journal Article
• Authors: Perez-Roman, Roberto J.; Lugo-Pico, Julian G.; Burks, Joshua D.; Madhavan, Karthik; Sheinberg, Dallas; Green, Barth A.; Gjolaj, Joseph P.
• Is Part Of: Journal of clinical neuroscience. Volume 66(2019)
• Page Start: 41
• Page End: 44
• Publication Date: 2019-08
• Subjects: Tranexamic acid -- Perioperative blood loss -- Posterior cervical decompression and fusion -- Safety; Brain -- Surgery -- Periodicals; Neurosciences -- Periodicals; Nervous system -- Surgery -- Periodicals; Brain -- surgery -- Periodicals; Neurosurgical Procedures -- Periodicals; Neurosciences -- Periodicals; Electronic journals; 616.8
• DOI: 10.1016/j.jocn.2019.05.029
• Languages: English
• ISSNs: 0967-5868

Abstract

Highlights: There were no intra- or post-operative thromboembolic or cardiovascular events in the TXA group. Some studies suggest that high doses of TXA may increase the risk of seizures, none of our patients experienced seizures. Intra-operative blood loss showed no statistically significance difference between the TXA and control group. Post-operative blood loss was reduced in the TXA group compared to the control group. Surgical time was significantly reduced in cases that TXA was administered. Abstract: Posterior cervical decompression and fusion (PCDF) can result in substantial blood loss, leading to blood transfusions and associated complications, such as infections, hypotension and organ damage. The antifibrinolytic tranexamic acid (TXA), an inhibitor of the activation of plasminogen, has been shown to be beneficial in multiple surgical procedures without any apparent increase in postoperative complications. However, there are only few studies reporting TXA utilization in cervical spine surgery and there is currently no literature detailing the short-term safety of its use in this setting. The purpose of our study is to determine the safety profile of TXA in posterior cervical decompression and fusion. From January 2015 to April 2018, 47 patients were identified to have undergone PCDF, 19 with the utilization of a TXA protocol at our institution. The incidence of adverse events was evaluated in the perioperative period and at 1 month follow-up. Of 39 patients, Nineteen (49%) received TXA as per our instructional protocol and 20 (51%) did not. Post-operative blood was significantly reduced (453 ml vs 701 ml; p = 0.03) in the group that received TXA. There was also a significant reduction in duration of surgery associated with TXA use (269 min vs 328 min; p = 0.05). There were no complications on the first 30 days after surgical intervention on the TXA group. TXA use during PCDF is a safe, effective method to reduce postoperative blood loss. Considering the limited number of patients in this study, these results should be validated on a larger group of patients.